WOCKHARDT

Saurabh Sharma
Sharad Suhane
Shashank Srivastava
Shreeram Sharma
Siddarth Tyagi
Shikha Sisodia
Introduction:-

Research and technological oriented pharmaceutical company founded in

1960s headquartered in Mumbai;India.

14 manufacturing plants in India,UK,Ireland ,France and US and

subsidiaries in US,UK,Ireland and France.

The company has the market capitalization of Rs.4,800 crore(US$ 1.7

billion) and an annual turn over of Rs.3,600 crore(US$ 802.8 million).
 There are more than 200 products in the global market and 71 more
products were launched in the FY 2010-11.
NUTRITI
ONALS
Wockhardt is the 4th Indian pharma company to be in the global elite
group of 100(Source-Scrip 100,2011 Edition).

In the domestic market, Wockhardt Group has a strong presence in more

than 50% of the therapeutic segments with therapy focused marketing
divisions. It has a significant presence in pain management, cough
therapy, psychotic drugs, diabetology, vaccines, nutrition and super
STRILES
specialty hospitals. PRODUCTS ORALS

BIOPHAR
MACEUT
ICLAS
 Wockhardt has fully ventured into one of the fastest
growing pharmaceutical business domains of
CRAMS eg.Byetta
Pharmaceutical and biotechnology major
wockhardt limited has forged in-licensing
agreement with sinclair pharma for dermatological
and dental products eg.Papulex,Atopiclair,Aloclair
The indian dermatological market is worth a
whooping 1782 crore.
 Wockhardt hospital showed impressive growth this year under the
direction of newly appointed M.D.Zahabiya khorakiwala.

During 2006 Wockhardt completed its largest acquisition to date

Pinewood health care to become a major player in the Irish generic
market.

Core speciality are heart care,brain and spine,bone and joint,laproscopic

and urology.
STRENGHTS
Strong expertise in the area of Recombinant
Biotechnology.
Strong ANDA pipeline.
Strong presence in the European market & U.S.
market.
Marketing of in-licensed products in INDIA.
Strong sales force in INDIA.
USFDA approved manufacturing facilities.
OPPORTUNITIES
Patent expiry of large pool of products.
New molecules under trial.
Research in the field of herbal medicines.
WEAKNESS
Nascent presence in the US market (Less than 10% contribution to total revenues)

Highly leveraged balance sheet with D/E ratio more than 1.5x.
THREATS
Pricing pressure in the US. restrict expected revenue growth (price erosion more
than 95%) specially in cephalosporin segment, with growing competition from
companies like Orchid Chemicals and Lupin.
Regulatory issues may delay approvals.
Any expensive acquisitions may increase payback period.
Increasing competition in the European generic market with the growing presence
of frontline Indian pharma companies including Ranbaxy and Reddys.
There is a risk of domestic currency appreciation as the company derives major
revenue from international operations (1 to 3% impact on operating profits for every
one rupee appreciation)
 Marketing and manufacturing synergies generated from
various acquisitions in the European market will help
the company improve net profit margin in excess of 15%.

Advantage of the low genericisation in these markets.

The companys revenue from the US market will grow

at a high rate due to low penetration and strong product
pipeline.

Focused on lifestyle disease segment in domestic market

 The domestic business will be above industry growth
due to significant presence in the chronic therapy
areas.

The companys expertise in biotechnology segment

will give it a huge opportunity of introducing bio-
generics in regulated markets.

The company may strike another lucrative acquisition

deal because it has huge cash available with it.